Inhibrx Biosciences, Inc. stays a Strong Buy with Q2 2026 ozekibart BLA catalyst, 2026 PFS data, and Ewing sarcoma updates.

Inhibrx Biosciences is vying for approval of its targeted therapy, ozekibart, in chondrosarcoma. This follows the positive outcome of the Phase II ChonDRAgon trial (NCT04950075), which found that ...

Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "Chondrosarcoma Market - A Global and Regional Analysis: Focus on Type, Treatment Type, and Region - Analysis and Forecast, 2025-2035" report has been ...

Mumbai: Dr Arsheed Hussain Hakeem, Senior Consultant – Surgical Oncology, Apollo Cancer Centre, Hyderabad speaking to Prabhat Prakash of ETHealthworld discussed the rarity of mesenchymal ...

Chondrosarcoma represents a heterogeneous group of primary malignant tumours arising from cartilaginous tissues. These tumours vary widely in clinical behaviour, ranging from slow-growing, locally ...

Please provide your email address to receive an email when new articles are posted on . The patient is a 57-year-old, right-handed, retired postal worker. He presented with a chief complaint of ...

Osteosarcoma (OS), chondrosarcoma, and chordoma are characterized by multiple challenges to the investigator, clinician, and patient. One consequence of their rarity among sarcomas, as well as their ...

SAN DIEGO, Oct. 22, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for ...

(RTTNews) - Inhibrx Biosciences, Inc. (INBX), a clinical-stage biopharmaceutical company, reported its third-quarter 2025 financial results and highlighted the upcoming events to watch in the coming ...